Palvella Therapeutics has appointed Matt Pauls, an experienced biotech executive with over 25 years in rare disease drug development and commercialization, to its Board of Directors. Pauls brings leadership from companies like Savara, Soleno, and Insmed, and will support Palvella's upcoming U.S. launch of QTORIN™ rapamycin and its pipeline for rare skin diseases and vascular malformations. This move strengthens Palvella's expertise as it advances therapies with no FDA-approved options. Pauls expressed enthusiasm about contributing to Palvella's growth during this pivotal phase.
The General Counsel of Figma has sold 211,599 shares, generating $6.3 million in proceeds. This significant insider sale could indicate personal financial planning or a shift in confidence, which investors might watch closely. The impact on Figma's s...
Lighter (LIT) surged 11.64% to $3.84 on Sept. 3, 2026, reaching a new all-time high with no confirmed catalyst. The rally is driven by momentum in a thin retail float, with 83.3% of volume flagged as wash trading. Key factors to watch include whether...
Rosen Law Firm has announced an investigation into potential securities claims against Tigo Energy, Inc. following allegations that the company issued materially misleading business information. This comes after Tigo Energy revised its 2026 income pr...
Binance Alpha added two new tokens, PONS and FLORK, on September 2, both experiencing significant price increases on their first day of trading. PONS, the native token of the Pons launchpad on Robinhood Chain, surged over 21%, reaching a market cap o...
Fidelity Digital Assets warns that future quantum computers could break Bitcoin's current cryptographic protections by deriving private keys from public keys, putting funds at risk. They highlight a proposed hash-based signature system called SHRINCS...
